DGAP-News: QUANTRO Therapeutics GmbH / Key word(s): Personnel
30.04.2021 / 10:00
QUANTRO Therapeutics appoints
Dr. Elmar Maier as Independent Board Chairman
Vienna, Austria, 30 April 2021: QUANTRO Therapeutics GmbH today announced the appointment of Dr. Elmar Maier as Independent Chairman of its Board.
Elmar has a long-standing track record as a seasoned dealmaker in the life science industry. Over the last 26 years, he has co-founded several biotech companies (including GPC Biotech AG and iOmx Therapeutics AG) and held C-level positions on multiple management teams in private and public biotech companies. He has helped biotech companies to establish large R&D collaborations generating several hundred million dollars cash up-front, raise significant equity funding and execute M&A transactions. Elmar holds a degree in chemistry and obtained his Ph.D. from the University of Konstanz, Germany. He was a scientist at the ICRF Laboratories in London and Department Head at the Ma
Rinri Therapeutics, a Sheffield, England, UK-based biotechnology company developing a novel stem cell therapy to restore hearing, raised a total of £10m in funding.
Backers included existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund.
The proceeds will support the development of the company’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL).
Led by Dr Simon Chandler, CEO, Rinri Therapeutics is a private biotechnology company developing advanced stem cell-based therapeutics to restore hearing. The company’s technology seeks to reverse sensorineural hearing loss (SNHL) through the repair of the damaged cytoarchitecture in the inner ear. There are currently no pharmacological treatment options for SNHL patients.
Search jobs Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund
Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund. The proceeds will support the development of the Company’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL).
Rinri’s underlying technology, based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield from where the company was spun out, seeks to reverse SNHL through the repair of the damaged cytoarchitecture in the inner ear. SNHL happens when there is damage to the hair cells in the cochlear and/or the auditory nerve. There are currently no pharmacological treatments available for SNHL despite t
Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss
News provided by
Share this article
Share this article
SHEFFIELD, England, April 20, 2021 /PRNewswire/ Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund. The proceeds will support the development of the Company s novel stem cell therapy to reverse sensorineural hearing loss (SNHL).
Rinri s underlying technology, based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield from where the company was spun out, seeks to reverse SNHL through the repair of the damaged cytoarchitecture in the inner ear. SNHL happens when there is damage to the hai
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
T-knife Therapeutics Announces the Appointment of Donald Wuchterl as Senior Vice President and .
AKAMPIONApril 7, 2021 GMT
San Francisco, CA / Berlin, Germany – April 7, 2021 T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing innovative therapeutics for the benefit of solid tumor patients and their families, today announced the appointment of Donald Wuchterl as Senior Vice President and Chief Manufacturing Officer. In this newly appointed role, Mr. Wuchterl will oversee process and analytical development, quality assurance and quality control, and viral vector and cell therapy manufacturing activities.
“I am very pleased to welcome Don to the T-knife team,” stated Thomas M. Soloway, Chief Executive Officer of T-knife. “Don’s proven track-record of building and leading highly functioning cell therapy, biologics and gene therapy manufacturing orga